We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.95B
1-Year Est. Return 773.9%
This Fund
S&P 500
This Quarter Est. Return
+19.76%
1 Year Est. Return
+773.9%
3 Year Est. Return
+3,976.92%
5 Year Est. Return
+17,750.67%
10 Year Est. Return
+592,782.78%
AUM
$1.95B
AUM Growth
-$39.6M
Cap. Flow
-$245M
Cap. Flow %
-12.56%
Top 10 Hldgs %
59.19%
Holding
59
New
12
Increased
4
Reduced
29
Closed
9

Top Buys

Rank Stock Value
1
PBLS
Parabilis Medicines Inc
PBLS
+$128M
2
CLYM
Climb Bio
CLYM
+$21.8M
3
FTH
Faeth Therapeutics
FTH
+$16.7M
4
SYRE icon
Spyre Therapeutics
SYRE
+$16.4M
5
ANL
Adlai Nortye Group ADS
ANL
+$13.1M

Top Sells

Rank Stock Value
1
PRAX icon
Praxis Precision Medicines
PRAX
+$77.7M
2
CNTA
Centessa Pharmaceuticals
CNTA
+$41.7M
3
EWTX icon
Edgewise Therapeutics
EWTX
+$25.9M
4
OLMA icon
Olema Pharmaceuticals
OLMA
+$23.4M
5
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$23.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.09%
2 Financials 0.91%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AXSM icon
51
Axsome Therapeutics
AXSM
$10.4B
– –
-50,000
Closed -$8.45M
CNTA
52
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-1,050,000
Closed -$41.7M
CNTX icon
53
Context Therapeutics
CNTX
$35.3M
– –
-529,550
Closed -$1.39M
GLUE icon
54
Monte Rosa Therapeutics
GLUE
$1.14B
– –
-400,000
Closed -$6.58M
OLMA icon
55
CALL
Olema Pharmaceuticals
OLMA
$899M
– –
-500,000
Closed -$7.46M
RLYB icon
56
Rallybio
RLYB
$89.3M
– –
-400,000
Closed -$3.59M
TERN
57
DELISTED
Terns Pharmaceuticals
TERN
– –
-300,000
Closed -$15.8M
ZURA icon
58
Zura Bio
ZURA
$548M
– –
-1,450,000
Closed -$8.63M
MAZE
59
Maze Therapeutics
MAZE
$1.52B
– –
-750,000
Closed -$22.4M
1 2
3

Similar funds

AHC
Adell Harriman & Carpenter Houston, Texas $1.95B AUM 52.72% 1-Year Est. Return
FFS
Founders Financial Securities Towson, Maryland $1.95B AUM 22.17% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.95B AUM 25.88% 1-Year Est. Return
BFPW
BOK Financial Private Wealth Denver, Colorado $1.95B AUM 20.52% 1-Year Est. Return
MSA
MUFG Securities Americas New York $1.95B AUM 42.71% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return

Cormorant Asset Management's Q2 2026 Portfolio in Review

As of Q2 2026, Cormorant Asset Management held 59 positions worth $1.95B, down 2% from $1.99B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Cormorant Asset Management withdrew a net $245M in Q2 2026, closing 9 positions and reducing 29 holdings. Its most notable exit was Centessa Pharmaceuticals, an estimated $41.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

Against the trend, Cormorant Asset Management opened a new position in Parabilis Medicines Inc worth $126M.

  • Cormorant Asset Management's largest Q2 2026 buy was Parabilis Medicines Inc: 4,615,612 shares worth $126M.
  • Cormorant Asset Management added most to Faeth Therapeutics in Q2 2026, an estimated $16.7M increase.
  • Cormorant Asset Management's biggest Q2 2026 reduction was Praxis Precision Medicines, cutting an estimated $77.7M.
  • Cormorant Asset Management fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $41.7M.
  • Cormorant Asset Management's ten largest holdings make up 59% of its $1.95B portfolio in Q2 2026.
  • Cormorant Asset Management opened 12 new positions and closed 9 in Q2 2026.
  • Cormorant Asset Management's portfolio value fell 2% quarter-over-quarter to $1.95B.

Based on Cormorant Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.